Tucatinib (ONT-380) progressing in pivotal trial against HER2+ breast cancer

(University of Colorado Anschutz Medical Campus) Twenty-seven percent of 50 heavily pretreated patients with stage IV HER2+ breast cancer saw clinical benefit from the drug, with at least 'stable disease' at 24 or more weeks after the start of treatment.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news